United Therapeutics Corporation
UTHR
$301.50
$2.080.70%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -3.94% | 6.94% | -2.52% | 11.15% | -9.30% |
| Total Depreciation and Amortization | 6.57% | 0.51% | 3.14% | 2.14% | 24.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.58% | 68.85% | -32.22% | -18.55% | 192.72% |
| Change in Net Operating Assets | -360.26% | 1,957.14% | -132.31% | 111.95% | -373.37% |
| Cash from Operations | -58.43% | 35.17% | -9.54% | 62.45% | -38.33% |
| Capital Expenditure | 16.96% | 13.61% | -13.33% | -69.62% | -18.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -164.70% | -146.03% | 4.95% | -10.03% | -104.51% |
| Cash from Investing | -82.09% | -33.69% | -7.22% | -43.63% | -110.88% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -300.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | -15.81% | -16.02% | -29.48% | -30.33% | 13.02% |
| Repurchase of Common Stock | 66.01% | -5,000.00% | 25.00% | -300.00% | 99.99% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -111.73% | -25.57% | -16.54% | -33.54% | 95.51% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -251.36% | 41.45% | -27.70% | 90.21% | 137.90% |